According to the report that pharmacological inhibition of Gal-3 in adenocarcinomic human alveolar basal epithelial cells significantly attenuates production of IL-17 and suggested pivotal role of Gal-3 in IL-17 mediated inflammation during experimental allergic asthma (Mammen et al., 2018), it can be assumed that Gal-3 deficiency could be protective during periodontal disease development. The gene discussed is LGALS3; the disease is allergic asthma.